Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, when he expects NICE to publish guidance on the use of bisphosphonates for the indication of preventing secondary breast cancer.

The National Institute for Health and Care Excellence’s (NICE) guideline on early and locally advanced breast cancer: diagnosis and management (CG80) recommends the use of adjuvant bisphosphonates for the management of breast cancer treatment-induced bone loss in specified clinical circumstances. This guideline is currently being updated and the use of adjuvant bisphosphonates has been identified as one of the key areas that will be covered in this update. NICE expects to publish its updated guideline in July 2018.